Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vaccine and antibody combo stop ebola after exposure?

NCT ID NCT05202288

Not yet recruiting Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether giving the Ervebo Ebola vaccine together with the antibody drug Inmazeb still works to protect people who may have been exposed to Ebola. The vaccine alone takes time to work, while antibodies act fast but might interfere with the vaccine. Researchers will give 132 healthy adults different combinations and timings to find the best approach for post-exposure protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ervebo (Ebola vaccine) and Inmazeb (antibody drug)
What this could lead to
If successful, this could show how to use both a vaccine and antibody together for better short- and long-term protection after Ebola exposure.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. The antibody might block the vaccine's effect, and results may not apply to real outbreaks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBOLA VIRUS DISEASE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.